We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat
Read MoreHide Full Article
BioMarin Pharmaceutical Inc. (BMRN - Free Report) reported lower-than-expected earnings for the first quarter of 2018 but beat estimates for sales.
First-quarter adjusted earnings of 12 cents per share were lower than the Zacks Consensus Estimate of 13 cents and year-ago earnings of 20 cents. Earnings decreased year over year due to higher operating costs, partially offset by increased gross margins. However, the company reported a loss of 26 cents per share including amortization, depreciation and stock-based compensation expenses.
Total revenues came in at $373.4 million, up 22.9% from the year-ago quarter driven by higher product revenues. Revenues also topped the Zacks Consensus Estimate of $348.16 million.
BioMarin’s shares fell almost 1.4% in after-market trading on Apr 25, presumably on the company’s lower-than-expected earnings. So far this year, BioMarin’s shares have slightly outperformed the industry. While BioMarin’s shares are down 8.6%, the industry has witnessed a decrease of 10.1%.
Quarterly Details
Product revenues were $369.1 million in the quarter, up 22.1% year over year, supported by continued strong demand for BioMarin’s marketed products. Royalty and other revenues were $4.3 million in the first quarter, compared with $1.6 million in the year-ago quarter.
Kuvan revenues rose 7% to $99.1 million, reflecting patient growth in North America and continued uptake internationally. The number of patients on Kuvan therapy in the United States increased 9% year over year.
Naglazyme sales fell 7% year over year to $75 million due to the timing of government orders in certain countries. However, the number of patients increased 4% year over year.
Vimizim contributed $117.1 million to total revenues, up 11% year over year. The drug continued to witness steady patient growth as the number of patients on Vimizim therapy increased 16% in the quarter.
Naglazyme and Vimzim revenues vary on a quarterly basis, primarily due to the timing of central government orders from some countries, mainly Brazil.
BioMarin received Aldurazyme royalties – totaling $66.1 million – from Sanofi’s (SNY - Free Report) Genzyme in the quarter. Royalties for Aldurazyme were $19.4 million in the year ago quarter. The significant increase in the royalty amount was due to the adoption of the new accounting standard and timing of sales to Genzyme.
The newest drug in BioMarin’s portfolio, Brineura, generated sales of $6.9 million in this quarter compared with $5.2 million in the fourth quarter of 2017. Brineura received approval for the treatment of children with CLN2 disease – a form of Batten disease – both in the United States and the EU in the first half of 2017. Its commercial launch is underway in the United States and EU.
Firdapse sales were up 20% year over year to $4.9 million.
Research and development (R&D) expenses were 26.9% higher year over year while selling, general and administrative (SG&A) expenses increased 15.3% in the quarter.
At the end of the first quarter of 2018, BioMarin had $1.7 billion in cash, cash equivalents and investments compared with $1.8 billion at the end of 2017.
Pipeline Update
In March 2018, BioMarin announced that the European Medicines Agency has accepted a Marketing Authorization Application for pegvaliase.
A FDA decision on its approval is expected late next month. Pegvaliase has been developed to treat phenylketonuria (“PKU”). The company said on the call that it is preparing for the launch in the United States.
Moreover, BioMarin has selected another gene therapy candidate for the treatment of PKU. An Investigational New Drug (“IND”) application to initiate studies on the candidate is expected to be filed next year in the United States.
BioMarin launched two separate phase III studies on valoctocogene roxaparvovec, its investigational gene therapy for severe hemophilia A. While one of these (GENEr8–1 study) is evaluating 6e13 vg/kg dose, the other one (GENEr8–2 study) is evaluating 4e13 vg/kg dose.
Another phase I/II study to evaluate a dose of 6e13 vg/kg of the candidate in patients producing neutralizing antibodies against AAV5 is likely to start this quarter.
Meanwhile, the global phase III program on another candidate, vosoritide for the treatment of children (ages 5-14) with achondroplasia (the most common form of dwarfism) continues to enroll as planned with top-line data expected in the second half of 2019.
In February 2018, the company presented interim data from a phase I/II study of BMN 250, evaluated for the treatment of Sanfilippo B syndrome or MPS IIIB. The data demonstrated normalization of an important biomarker and liver size, as well as suggested stabilization in cognitive decline.
Meanwhile, BioMarin is expected to file an IND this year for BMN-290, which will be developed for the treatment of Friedreich's ataxia, a rare autosomal recessive disorder.
2018 Outlook Maintained
BioMarin continues to expects total revenues in the range of $1.47 −$1.53 billion in 2018. The Zacks Consensus Estimate is pegged at $1.49 billion.
Vimizim sales are expected in the range of $460–$500 million. Kuvan sales are projected in the range of $440–$480 million, an increase of about 13% from 2017. Naglazyme sales are projected in the range of $325−$355 million. Brineura sales are expected in the range of $35–$55 million
Expenses related to R&D are expected within $645-$685 million while SG&A expenses are projected in the range of $575-$615 million.
The company expects adjusted net income in the range of $100 - $140 million.
BioMarin Pharmaceutical Inc. Price, Consensus and EPS Surprise
Ligand’s earnings per share estimates have moved up from $3.92 to $4.40 for 2018 and from $4.75 to $5.32 for 2019 in the last 60 days. The company delivered a positive earnings surprise in three out of the trailing four quarters, with an average beat of 24.88%. Share price of the company has increased 13% in a year.
Estimates for Alkermes have moved up from a loss of 12 cents to 9 cents for 2018 but decreased from 89 cents to 57 cents for 2019 in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 68.16%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat
BioMarin Pharmaceutical Inc. (BMRN - Free Report) reported lower-than-expected earnings for the first quarter of 2018 but beat estimates for sales.
First-quarter adjusted earnings of 12 cents per share were lower than the Zacks Consensus Estimate of 13 cents and year-ago earnings of 20 cents. Earnings decreased year over year due to higher operating costs, partially offset by increased gross margins. However, the company reported a loss of 26 cents per share including amortization, depreciation and stock-based compensation expenses.
Total revenues came in at $373.4 million, up 22.9% from the year-ago quarter driven by higher product revenues. Revenues also topped the Zacks Consensus Estimate of $348.16 million.
BioMarin’s shares fell almost 1.4% in after-market trading on Apr 25, presumably on the company’s lower-than-expected earnings. So far this year, BioMarin’s shares have slightly outperformed the industry. While BioMarin’s shares are down 8.6%, the industry has witnessed a decrease of 10.1%.
Quarterly Details
Product revenues were $369.1 million in the quarter, up 22.1% year over year, supported by continued strong demand for BioMarin’s marketed products. Royalty and other revenues were $4.3 million in the first quarter, compared with $1.6 million in the year-ago quarter.
Kuvan revenues rose 7% to $99.1 million, reflecting patient growth in North America and continued uptake internationally. The number of patients on Kuvan therapy in the United States increased 9% year over year.
Naglazyme sales fell 7% year over year to $75 million due to the timing of government orders in certain countries. However, the number of patients increased 4% year over year.
Vimizim contributed $117.1 million to total revenues, up 11% year over year. The drug continued to witness steady patient growth as the number of patients on Vimizim therapy increased 16% in the quarter.
Naglazyme and Vimzim revenues vary on a quarterly basis, primarily due to the timing of central government orders from some countries, mainly Brazil.
BioMarin received Aldurazyme royalties – totaling $66.1 million – from Sanofi’s (SNY - Free Report) Genzyme in the quarter. Royalties for Aldurazyme were $19.4 million in the year ago quarter. The significant increase in the royalty amount was due to the adoption of the new accounting standard and timing of sales to Genzyme.
The newest drug in BioMarin’s portfolio, Brineura, generated sales of $6.9 million in this quarter compared with $5.2 million in the fourth quarter of 2017. Brineura received approval for the treatment of children with CLN2 disease – a form of Batten disease – both in the United States and the EU in the first half of 2017. Its commercial launch is underway in the United States and EU.
Firdapse sales were up 20% year over year to $4.9 million.
Research and development (R&D) expenses were 26.9% higher year over year while selling, general and administrative (SG&A) expenses increased 15.3% in the quarter.
At the end of the first quarter of 2018, BioMarin had $1.7 billion in cash, cash equivalents and investments compared with $1.8 billion at the end of 2017.
Pipeline Update
In March 2018, BioMarin announced that the European Medicines Agency has accepted a Marketing Authorization Application for pegvaliase.
A FDA decision on its approval is expected late next month. Pegvaliase has been developed to treat phenylketonuria (“PKU”). The company said on the call that it is preparing for the launch in the United States.
Moreover, BioMarin has selected another gene therapy candidate for the treatment of PKU. An Investigational New Drug (“IND”) application to initiate studies on the candidate is expected to be filed next year in the United States.
BioMarin launched two separate phase III studies on valoctocogene roxaparvovec, its investigational gene therapy for severe hemophilia A. While one of these (GENEr8–1 study) is evaluating 6e13 vg/kg dose, the other one (GENEr8–2 study) is evaluating 4e13 vg/kg dose.
Another phase I/II study to evaluate a dose of 6e13 vg/kg of the candidate in patients producing neutralizing antibodies against AAV5 is likely to start this quarter.
Meanwhile, the global phase III program on another candidate, vosoritide for the treatment of children (ages 5-14) with achondroplasia (the most common form of dwarfism) continues to enroll as planned with top-line data expected in the second half of 2019.
In February 2018, the company presented interim data from a phase I/II study of BMN 250, evaluated for the treatment of Sanfilippo B syndrome or MPS IIIB. The data demonstrated normalization of an important biomarker and liver size, as well as suggested stabilization in cognitive decline.
Meanwhile, BioMarin is expected to file an IND this year for BMN-290, which will be developed for the treatment of Friedreich's ataxia, a rare autosomal recessive disorder.
2018 Outlook Maintained
BioMarin continues to expects total revenues in the range of $1.47 −$1.53 billion in 2018. The Zacks Consensus Estimate is pegged at $1.49 billion.
Vimizim sales are expected in the range of $460–$500 million. Kuvan sales are projected in the range of $440–$480 million, an increase of about 13% from 2017. Naglazyme sales are projected in the range of $325−$355 million. Brineura sales are expected in the range of $35–$55 million
Expenses related to R&D are expected within $645-$685 million while SG&A expenses are projected in the range of $575-$615 million.
The company expects adjusted net income in the range of $100 - $140 million.
BioMarin Pharmaceutical Inc. Price, Consensus and EPS Surprise
BioMarin Pharmaceutical Inc. Price, Consensus and EPS Surprise | BioMarin Pharmaceutical Inc. Quote
Zacks Rank & Stocks to Consider
BioMarin carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the biotech sector are Ligand Pharmaceuticals Incorporated (LGND - Free Report) and Alkermes plc (ALKS - Free Report) . While Ligand sports a Zacks Rank #1 (Strong Buy), Alkermes carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up from $3.92 to $4.40 for 2018 and from $4.75 to $5.32 for 2019 in the last 60 days. The company delivered a positive earnings surprise in three out of the trailing four quarters, with an average beat of 24.88%. Share price of the company has increased 13% in a year.
Estimates for Alkermes have moved up from a loss of 12 cents to 9 cents for 2018 but decreased from 89 cents to 57 cents for 2019 in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 68.16%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>